meta-analysis | Q815382 |
scholarly article | Q13442814 |
P2093 | author name string | Julia Wenger | |
David J A Goldsmith | |||
Ravi Thadhani | |||
Reza Hajhosseiny | |||
Hector Tamez | |||
Martin H de Borst | |||
P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 | ||
Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data | Q30656350 | ||
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials | Q33413288 | ||
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials | Q33836604 | ||
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis | Q34120189 | ||
The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis | Q34122611 | ||
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients | Q34123786 | ||
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. | Q34254721 | ||
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria | Q34504490 | ||
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial | Q34625011 | ||
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis | Q34660044 | ||
1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system | Q34793842 | ||
Changes in albuminuria predict mortality and morbidity in patients with vascular disease | Q35108899 | ||
Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease | Q35210184 | ||
Sodium intake, ACE inhibition, and progression to ESRD. | Q35720736 | ||
Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease | Q36227387 | ||
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis | Q36336393 | ||
Estimating the financial cost of chronic kidney disease to the NHS in England | Q36358702 | ||
Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease | Q36431285 | ||
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials | Q36567554 | ||
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure | Q36902283 | ||
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase | Q36924964 | ||
Chronic kidney disease, hypovitaminosis D, and mortality in the United States | Q37216938 | ||
Age and association of kidney measures with mortality and end-stage renal disease | Q37606084 | ||
Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. | Q39289974 | ||
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 | ||
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts | Q41931102 | ||
The GFR and GFR decline cannot be accurately estimated in type 2 diabetics | Q43588428 | ||
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria | Q44445107 | ||
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. | Q45930492 | ||
Renal protective effect of enalapril in diabetic nephropathy | Q46080832 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial | Q46497289 | ||
Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy? | Q46529781 | ||
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials | Q46567269 | ||
Kidney function as a predictor of noncardiovascular mortality | Q46776022 | ||
Antiproteinuric effect of oral paricalcitol in chronic kidney disease | Q46826570 | ||
Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate | Q48836184 | ||
1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. | Q51578714 | ||
Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. | Q53551859 | ||
Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial | Q57702534 | ||
Vitamin D levels and early mortality among incident hemodialysis patients | Q63681909 | ||
Renal function during calcitriol therapy in chronic renal failure | Q68724185 | ||
Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group | Q73632528 | ||
Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure | Q78197798 | ||
Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy | Q79326178 | ||
Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial | Q82147201 | ||
An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease | Q84199625 | ||
P433 | issue | 11 | |
P921 | main subject | vitamin | Q34956 |
systematic review | Q1504425 | ||
vitamin D | Q175621 | ||
P304 | page(s) | 1863-1871 | |
P577 | publication date | 2013-08-08 | |
P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
P1476 | title | Active vitamin D treatment for reduction of residual proteinuria: a systematic review | |
P478 | volume | 24 |